

September 01, 2026

To,

The General Manager, Listing Compliance Department, Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Mumbai – 400 001 Company code: 533333	The Manager, Listing & Compliance Department The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Company code: FCL
--	---

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) – Incorporation of a Wholly Owned Step-down Subsidiary

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations, we wish to inform you that Fineotex Biotex HealthGuard FZE (“FZE Company”), a wholly owned subsidiary of the Company, has incorporated a new wholly-owned step-down subsidiary named Fineotex Holdings Inc. (“FHI”), in USA.

The Company has received intimation today, 1st September, 2026 that the Certificate of Incorporation of FHI has been issued by the State of Delaware, USA.

In this regard, please find enclosed herewith the disclosure containing details as required under Regulation 30(6) read with clause (1) of Para A of Part A of Schedule III of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as ‘Annexure - A’.

The above information is also available on the website of the Company www.fineotex.com.

You are requested to kindly take the above on record.

Thanking you,

Yours faithfully,
For FINEOTEX CHEMICAL LIMITED

Sanjay Tibrewala
Executive Director
DIN: 00218525



Encl: As above

Annexure – A

SN.	Details of Events required to be disclosed	Disclosures
1	Name of the target entity, details in brief such as size, turnover etc.	Fineotex Holdings Inc. The above company is newly incorporated and therefore the turnover is Nil.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Wholly Owned Subsidiary is a related party of Fineotex Chemical Limited (“the Company”)
3	Industry to which the entity being acquired belongs	Specialty Chemicals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The object of Fineotex Holdings Inc to undertake specialty chemical and allied business activities, including manufacturing, trading and development of specialty chemicals, and to pursue strategic investments, acquisitions and other growth opportunities in related or allied businesses.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Nature of consideration - whether cash consideration or share swap and details of the same	Not Applicable
8	Cost of acquisition or the price at which the shares are acquired	Not Applicable
9	Percentage of shareholding/control acquired and/ or number of shares acquired	Fineotex Biotex HealthGuard FZE a wholly owned subsidiary of the Company, holds 100% share capital of Fineotex Holdings Inc.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Fineotex Holdings Inc is newly incorporated in USA and registered with State of Delaware, USA.